An Open, Multicenter, Randomized, Dose-Ranging Study of Azithromycin in the Treatment of Disseminated Mycobacterium Avium-Intracellulare Complex Infection (MAC) in Patients With Acquired Immune Deficiency Syndrome (AIDS)

Inclusion Criteria Concurrent Medication: Allowed: * Medications allowed under a Treatment IND program. Patients must have: * HIV infection. * Disseminated Mycobacterium avium Complex. * Fever (\> 100 degrees F) that cannot be attributed to another active infection, and at least one other constitutional symptom (such as fatigue, malaise, anorexia). * Life expectancy of at least the duration of the study. * Consent of parent or guardian if below the legal age of consent. Exclusion Criteria Co-existing Condition: Patients with the following symptoms and conditions are excluded: * Known hypersensitivity or significant intolerance to macrolide antibiotics. * Inability to take oral medications or a current condition likely to interfere with drug absorption (e.g., gastrectomy). Prior Medication: Excluded: * Treatment with an immunostimulant or immunomodulator compound such as alpha-interferon, gamma-interferon, or any interleukin within 7 days prior to study entry. * Any other antibiotic with known activity against M. avium within 7 days prior to study entry. Not expected to comply with the requirements of the protocol, in the opinion of the investigator.